Free Trial
NASDAQ:QNTM

Quantum Biopharma 5/14/2025 Earnings Report

Quantum Biopharma logo
$24.37 -2.76 (-10.17%)
Closing price 04:00 PM Eastern
Extended Trading
$23.98 -0.39 (-1.58%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Quantum Biopharma EPS Results

Actual EPS
-$1.41
Consensus EPS
-$0.37
Beat/Miss
Missed by -$1.04
One Year Ago EPS
N/A

Quantum Biopharma Revenue Results

Actual Revenue
$2.09 million
Expected Revenue
$2.09 million
Beat/Miss
Beat by +$2.00 thousand
YoY Revenue Growth
N/A

Quantum Biopharma Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Quantum Biopharma's next earnings date is estimated for Wednesday, August 13, 2025, based on past reporting schedules.

Conference Call Resources

Quantum Biopharma Earnings Headlines

Q1 Earnings Forecast for QNTM Issued By Singular Research
A new rule goes live in July — and the banks are quietly cashing in
A major change is quietly going into effect this July — and Wall Street is already positioning for it. Big Banks have found a way to use a new asset as if it were cash. Not stocks. Not bonds. Not even the U.S. dollar. They now trust this asset more than the traditional financial system itself.
Quantum, CyberCatch, Kodiak at 52-Week Highs on News
Keg, LQWD, Quantum at 52-Week Highs on News
See More Quantum Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Quantum Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Quantum Biopharma and other key companies, straight to your email.

About Quantum Biopharma

Quantum Biopharma (NASDAQ:QNTM) is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for neurodegenerative diseases, including Lucid-MS, a first-in-class small molecule drug candidate designed to promote remyelination in patients with Multiple Sclerosis (MS).

View Quantum Biopharma Profile

More Earnings Resources from MarketBeat